Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice

Atheroregressive Potential of the Treatment with a Chimeric Monoclonal Antibody against Sulfated Glycosaminoglycans on Pre-existing Lesions in Apolipoprotein E-Deficient Mice

The retention of lipoprotein particles in the intima, in particular to glycosaminoglycan side chains of proteoglycans, is a critical step in atherosclerosis initiation. Administration of chP3R99, a chimeric mouse/human monoclonal antibody inducing an anti-idiotypic network response against glycosami...

Full description

Bibliographic Details
Main Authors: Victor Brito, Katia Mellal, Karina F. Zoccal, Yosdel Soto, Liliane Ménard, Roger Sarduy, Lucia H. Faccioli, Huy Ong, Ana M. Vázquez, Sylvie Marleau
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-11-01
Series:Frontiers in Pharmacology
Subjects:
proteoglycans
glycosaminoglycans
atherosclerosis
active immunization
regression
interleukin-6
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00782/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00782/full

Similar Items